You just read:

ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV

News provided by

ViiV Healthcare

03 Sep, 2014, 15:05 BST